BrainCheck, Inc., a digital health innovator delivering next-generation technology into the growing digital cognitive assessment market, announced a new study published in Frontiers in Psychology ...

Outcomes may improve with disease-modifying drugs and lifestyle change if Alzheimer's could be identified earlier.

Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment ...

Dementia in Parkinson disease occurs less frequently or much later in the disease course than previously expected.

The analysis included 405 students (aged 18 to 30 years). The researchers found that both vape frequency and user type had a ...

Baseline small vessel disease score is the strongest predictor for incident infarcts among patients with a history of stroke.

Donald Trump could enter the Oval Office with cardiac risk factors, possible aftereffects from the July assassination attempt and the cognitive decline that naturally comes with age.

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Cultural observers. Sonic collage experts. Indie music darlings. Negativland returns to Cleveland to perform after a 24-year ...

Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues ...

(Clarinda) -- The Clarinda Regional Health Center has added a new member to its healthcare team.